Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of vascular endothelial growth factor (VEGF) in pathogenesis of AE-ILD is conflicting. The influence of bevacizumab (Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Shohei, Ichiyasu, Hidenori, Ikeda, Tokunori, Inaba, Megumi, Kashiwabara, Kosuke, Sadamatsu, Tomoki, Sato, Nahoko, Akaike, Kimitaka, Okabayashi, Hiroko, Saruwatari, Koichi, Tomita, Yusuke, Saeki, Sho, Hirata, Naomi, Yoshinaga, Takeshi, Fujii, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446385/
https://www.ncbi.nlm.nih.gov/pubmed/30940113
http://dx.doi.org/10.1186/s12890-019-0838-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446385/
https://www.ncbi.nlm.nih.gov/pubmed/30940113
http://dx.doi.org/10.1186/s12890-019-0838-2

Ejemplares similares